Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration.
The pharmacokinetics of the diuretic compound 4-phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid (piretanide, Arelix) were investigated in 10 healthy male volunteers following intravenous and intramuscular administration of single doses of 6 mg. Plasma concentration-time data followed in general characteristics of a three-compartment model. Following intravenous administration, the terminal half-life of elimination was 1.29 +/- 0.40 h, the total clearance 219 +/- 36 ml/min and the steady state volume of distribution was calculated to be 12.4 +/- 2.1 l. The renal excretion of unchanged drug amounted to 34.4 +/- 6.9% of the dose. Following intramuscular administration, peak plasma concentrations of 366 +/- 85 mg/ml were achieved 13.8 +/- 4.8 min after administration. All other parameters were not statistically significantly different from those obtained after i.v. bolus. The bioavailability of piretanide following intramuscular administration was 0.88 +/- 0.17.